Showing results for "Iveric Bio"
business
Asia Bankers Pick Japan as M&A’s Next Big ThingHi, it’s Manuel Baigorri in Hong Kong. I spoke to dealmakers here who’ve been hopping on (relatively short) flights to Japan—and not just for the amazing sushi. Elsewhere, Microsoft-Activision hits a blockade and Deutsche taps rivals for a FIG boost. Today's top storiesJune 14, 2023
markets
Astellas Pharma CEO Says Confident of Iveric Bio Drug ApprovalNaoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, for about $5.9 billion. He also talks about Astellas Pharma's growth strategy with Shery Ahn and Haidi Stroud-Watts on "Bloomberg Daybreak: Asia." (Source: Bloomberg)May 1, 2023
business
A Look at Why JPMorgan Came in As First Republic’s New Owner After Bidding WarHi, it’s Matt Monks in New York looking at how JPMorgan’s incredible heft enabled it to come out on top the sales process for First Republic. We also have a biotech deal and some fresh cross-border activity. Today's top storiesMay 1, 2023
industries
AbbVie, Bristol Myers Vied for Prometheus Before Merck Bought ItMerck & Co. edged out competitors including AbbVie Inc. and Bristol Myers Squibb Co. to prevail in its $10.8 billion takeover of biotechnology company Prometheus Biosciences Inc, according to people familiar with the matter.May 1, 2023
pursuits
JPMorgan Buys First Republic, Virginia Beach Tornado: Trending TodayWelcome to Social Buzz, a daily column looking at what’s trending on social media platforms. I’m Caitlin Fichtel, an editor on Bloomberg’s Breaking News team, which monitors everything from company statements to tweets from some of the most prominent people in the financial world. Here’s your daily look at what the internet is talking about.May 1, 2023